CT-P13: Clinical Trials

4 trials of CT-P13, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 recruiting, 1 unknown. 4 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1
Phase 22Active not recruiting 1, Unknown 1

Follow CT-P13: new trials by email Literature Review of CT-P13 trials Research Report on CT-P13

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
Infliximab-dyyb Biosimilar (Remsima) - Moderate to Severe Chronic Plaque Psoriasis
Phase 1 / Phase 2UnknownServices Institute of Medical Sciences, Pakistan1042023-11-062024-09-19
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Phase 1RecruitingM.D. Anderson Cancer Center8002021-02-212026-07-15
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
Infliximab, Vedolizumab - Colitis, Lung Non-Small Cell Carcinoma
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center472020-07-092026-07-15
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
CT-P13 - Crohn's Disease, Ulcerative Colitis (Part 2 Only)
Phase 1CompletedCelltrion1812016-09-292020-06-09

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Colitis (2)  ·  Urogenital Neoplasms (2)  ·  Colitis, Ulcerative (1)  ·  Crohn Disease (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  Celltrion (1)  ·  Services Institute of Medical Sciences, Pakistan (1)

Countries

United States (2)  ·  Pakistan (1)  ·  South Korea (1)

Top investigators

Yinghong Wang (2)  ·  Dr Hira Tariq, MBBS, FCPS Derma (1)  ·  MoonSun Choi (1)

Results publications

PMID 33676969, PMID 37004656, PMID 38365502

NIH funding

2016 (1)